NYSE:VNRX VolitionRx (VNRX) Stock Price, News & Analysis $0.52 0.00 (-0.13%) Closing price 04:00 PM EasternExtended Trading$0.52 +0.00 (+0.10%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About VolitionRx Stock (NYSE:VNRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VolitionRx alerts:Sign Up Key Stats Today's Range$0.51▼$0.5350-Day Range$0.46▼$0.6252-Week Range$0.42▼$0.90Volume145,299 shsAverage Volume175,100 shsMarket Capitalization$52.35 millionP/E RatioN/ADividend YieldN/APrice Target$3.33Consensus RatingModerate Buy Company OverviewVolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.Read More… VolitionRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreVNRX MarketRank™: VolitionRx scored higher than 34% of companies evaluated by MarketBeat, and ranked 716th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingVolitionRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVolitionRx has only been the subject of 2 research reports in the past 90 days.Read more about VolitionRx's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of VolitionRx is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VolitionRx is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for VNRX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVolitionRx does not currently pay a dividend.Dividend GrowthVolitionRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for VNRX. News and Social Media1.8 / 5News Sentiment0.30 News SentimentVolitionRx has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for VolitionRx this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added VolitionRx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, VolitionRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.80% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.09% of the stock of VolitionRx is held by institutions.Read more about VolitionRx's insider trading history. Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address VNRX Stock News HeadlinesVolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoptionMay 7 at 8:30 AM | prnewswire.comVolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar marketsApril 29, 2025 | prnewswire.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 7, 2025 | Golden Portfolio (Ad)VolitionRx enters new sales agreement, terminates old oneApril 24, 2025 | investing.comVolitionRx initiated with a Buy at H.C. WainwrightApril 8, 2025 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationApril 8, 2025 | msn.comEarnings call transcript: VolitionRx revenue beats forecast in Q4 2024April 2, 2025 | investing.comVolitionRx outlines 2025 licensing goals and targets cash neutrality with strategic expansionsApril 1, 2025 | msn.comSee More Headlines VNRX Stock Analysis - Frequently Asked Questions How have VNRX shares performed this year? VolitionRx's stock was trading at $0.60 on January 1st, 2025. Since then, VNRX shares have decreased by 13.4% and is now trading at $0.5195. View the best growth stocks for 2025 here. How were VolitionRx's earnings last quarter? VolitionRx Limited (NYSE:VNRX) posted its quarterly earnings results on Monday, March, 25th. The company reported ($0.11) earnings per share for the quarter. The company earned $0.24 million during the quarter, compared to the consensus estimate of $0.50 million. How do I buy shares of VolitionRx? Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VolitionRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRx investors own include BlackRock Innovation and Growth Term Trust (BIGZ), FS KKR Capital (FSK), Guggenheim Strategic Opportunities Fund (GOF), 3M (MMM), OFS Credit (OCCI), XAI Octagon Floating Rate & Alternative Income Trust (XFLT) and Broadcom (AVGO). Company Calendar Last Earnings3/25/2024Today5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNYSE:VNRX CIK93314 WebN/A Phone646-650-1351Fax65 32 8172 5651Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$3.33 High Stock Price Target$5.00 Low Stock Price Target$2.50 Potential Upside/Downside+536.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,320,000.00 Net Margins-2,321.14% Pretax Margin-2,346.62% Return on EquityN/A Return on Assets-163.39% Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.22 Sales & Book Value Annual Sales$1.23 million Price / Sales42.81 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-4.76Miscellaneous Outstanding Shares100,775,000Free Float80,804,000Market Cap$52.81 million OptionableOptionable Beta1.00 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NYSE:VNRX) was last updated on 5/7/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.